Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 for Steroid-refractory Chronic GVHD
NCT02086513Phase 1Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2014
- Primary completion
- Dec 2016
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonidegib in graft-versus-host disease (GVHD), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Apr 2014; status: terminated.
02
Drugs
sonidegib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02086513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086513.